Clinical Trial Update: Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

This update reports that a Phase 2 trial of ispinesib in platinum-taxane-refractory or resistant relapsed ovarian cancer has completed. Sponsor is GlaxoSmithKli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Ispinesib (ispinesib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED